The Fatal Self Distraction of the Academic Publishing Industry: The Solution of the Open Access Online Scientific Journals
Curator: Aviva Lev-Ari, PhD, RN
Crisis Dimensionality of the Academic Publishing Industry
How to break free from the tyranny of luxury journals (The Conversation)
Nobel winner declares boycott of top science journals by Ian Sample, science correspondent The Guardian, Monday 9 December 2013 14.42 EST
Pondering Science Publishing (The Scientist)
The problem with Science (and Nature) (The Economist)
Nobel laureate attacks ‘luxury journals’ (Times Higher Education)
Is Open Access Finally on the Ascendancy?(Biosciencemag)
NIH To Enforce OA Policy (The Scientist)
Is the Academic Publishing Industry on the Verge of Disruption? (U.S. News)
Other related articles published in this Open Access Online Scientific Journal include the following:
e-Recognition via Friction-free Collaboration over the Internet: “Open Access to Curation of Scientific Research by Aviva Lev-Ari, PhD, RN
Digital Publishing Promotes Science and Popularizes it by Access to Scientific Discourse by Aviva Lev-Ari, PhD, RN
Curation is Uniquely Distinguished by the Historical Exploratory Ties that Bind by Larry H Bernstein, MD, FCAP
“Open Access Publishing” is becoming the mainstream model: “Academic Publishing” has changed Irrevocably by Aviva Lev-Ari, PhD, RN
We present here FOUR alternative models to the Academic Publishing Industry
Alternative #1
PeerJ MODEL for Open Access Online Scientific Journal
The Peer J Scientific Online Journal introduces the need for this new order of publication as follows:
We are fully aware that being appropriately indexed and maximally discoverable is extremely important for our authors. We understand that you publish your research so that others can discover, read, discuss, cite and build upon it. If no one can discover, let alone read, the article that you spent years researching, and months writing, then it was pointless to even publish it in the first place.
We see that Open Access, and the associated benefits of open and early sharing are increasingly being understood by academia; and finally we hear from a lot of scientists who are now looking for a suitable preprint venue for their work.
http://blog.peerj.com/post/47445954946/ http://blog.peerj.com/post/47030855181/
This journal has full legitimacy as an acceptable peer reviewed publication for researchers who are already establish researchers publishing in their professional society publications, and for young academic professionals who need to establish a publication resume for academic advancement.This has become very important because of the long timelines for research publications in peer reviewed journals, and the effect on establishing an earned reputation needed for advancement.
Alternative #2
Read Cube
http://www.readcube.com/#features
ReadCube is an architecture for workflow efficient citation that is compatible with
- writing ,
- managing a collection of papers, and
- annotation and
improves the creation of a readable PDF. What app does it uniquely provide in one program?
- Enhanced PDF
- Supplements
- Clickable inline references
- Full reference list
- Editor summaries
- Related articles
- Inline notes and highlights
- Recommendations
- Instant searchability
- Bookmarklet
- Tablet compatible
- Sync and Backup
The features enumerated are not trivial. When writing for scientific publication, the
- finding of relevant related research publication, and
- adequate citation of other work is both important and laborious
- in constructing the discussion and support of a novel concept.
Evaluation of Alternative #1 and #2
Larry H Bernstein, MD, FCAP
These two developments are a strong emergence of a process as significant as Guttenberg’s introduction of the printing press, which opened the door to a
- flourishing Western Culture enriched by
- theater, opera, literary arts, journals, and the newspaper.
Just as the newspaper, radio, television, and the traditional movie have been in transformation in response to an
- all the time noisy and stressfully hard to discern target audience,
- the scholarly publications are under pressure to change and to go to the next level.
These two events are followed by the announcement of eLife, in life sciences research.
I tip my hat to IBMs Watson for creating a vision of man and computer as partners, although it was perhaps germinated by the earlier work by the physician who
- first created the structure for the medical record, then went on without the technology we have today
- to create the first feasible, but labor intensive EHR.
The ICHOR lab system was first to focus on WORKFLOW, but it also
- did not have the advantages of technology that emerged in the last decade.
In a separate parallel advance, Eugene Rypka in Albuquerque advance the feature extraction and analysis of bacterial classification. Then, Rosser Rudolf showed that it
had an underlying structure related to Solomon Kullback’s work on entropy, calling it “effective information”. We now use Akaike and Bayes information criteria as measures of classification adequacy.
Alternative #3
eLife is a collaboration between the Howard Hughes Medical Institute, the Max Planck Society, the Wellcome Trust, and over 200 of the world’s most talented biomedical scientists.
eLife is a unique collaboration between funders and practitioners of research to communicate influential discoveries in the life and biomedical sciences in the most effective way.
We are a joint initiative of the Howard Hughes Medical Institute, the Max Planck Society, and the Wellcome Trust. Along with a growing number of public and private research funders worldwide, these three organisations recognise that the communication of research results is as fundamental a component of the research process as the experiments themselves. Disseminating new findings as widely and effectively as possible maximises the value of research investments. The first step in the initiative is to establish a new, open-access venue for the most important advances — from basic biological research through to applied, translational and clinical studies.
The eLife journal will be a platform for extending the reach and influence of new discoveries and to showcase new approaches to the presentation, use, and assessment of research.
eLife is not just a journal. That’s just the beginning.
VIEW VIDEO
http://www.elifesciences.org/about/
Our initiative has four aims:
- To make publishing more efficient, by providing outstanding service to authors through a swift, constructive, and fair editorial process.
- To exploit digital media in the presentation of results, by increasing their utility for further research and broadening participation to the widest possible audience.
- To drive open access, by providing an outstanding new publishing option for authors with ground-breaking research.
- To catalyse innovation in research communication, by experimentation, collaboration, and continuous improvement.
eLife Sciences Publications, Ltd is a limited liability non-profit non-stock 501(c)3 corporation incorporated in the State of Delaware, USA, with company number 5030732, and is registered in the UK with company number FC030576 and branch number BR015634 at the address 1st Floor, 24 Hills Road, Cambridge CB2 1JP.
The eLife journal (ISSN 2050-084X) is published by eLife Sciences Publications, Ltd.
Alternative #4
http://pharmaceuticalintelligence.com
This alternative model for Scientific Publishing involve the following steps:
#1: CURATION and Co-CURATION of Scientific articles in conjunction with Experts, Authors, Writers critique and synthesis
Examples
- Erythropoietin (EPO) and Intravenous Iron (Fe) as Therapeutics for Anemia in Severe and Resistant CHF: The Elevated N-terminal proBNP Biomarker
Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/12/10/epo-as-therapeutics-for-anemia-in-chf/
- Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO(rivaroxaban) or PRADAXA (dabigatran)
Vivek Lal, MBBS, MD, F.Cl.R, Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
- Alternative Designs for the Human Artificial Heart: The Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community
Larry H. Bernstein, MD, FCAP, Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
#2: Assembly of articles into e-Books using ONE of a Kind electronic Table of Contents (eTOCs) architecture
Example
Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
This e-Book has the following Parts:
PART 1
Genomics and Medicine
Introduction to Volume Three
1.1 Genomics and Medicine: The Physician’s View
1.2 Ribozymes and RNA Machines – Work of Jennifer A. Doudna
1.3 Genomics and Medicine: Contributions of Genetics and Genomics to Cardiovascular Disease Diagnoses
1.4 Genomics in Medicine – Establishing a Patient-Centric View of Genomic Data
PART 2
Epigenetics – Modifiable Factors Causing Cardiovascular Diseases
2.1 Diseases Etiology
2.1.1 Environmental Contributors Implicated as Causing Cardiovascular Diseases
2.1.2 Diet: Solids and Fluid Intake and Nutraceuticals
2.1.3 Physical Activity and Prevention of Cardiovascular Diseases
2.1.4 Psychological Stress and Mental Health: Risk for Cardiovascular Diseases
2.1.5 Correlation between Cancer and Cardiovascular Diseases
2.1.6 Medical Etiologies for Cardiovascular Diseases: Evidence-based Medicine – Leading DIAGNOSES of Cardiovascular Diseases, Risk Biomarkers and Therapies
2.1.7 Signaling Pathways
2.1.8 Proteomics and Metabolomics
2.2 Assessing Cardiovascular Disease with Miomarkers
2.2.1 Issues in Genomics of Cardiovascular Diseases
2.2.2 Endothelium, Angiogenesis, and Disordered Coagulation
2.2.3 Hypertension BioMarkers
2.2.4 Inflammatory, Atherosclerotic and Heart Failure Markers
2.2.5 Myocardial Markers
2.3 Therapeutic Implications: Focus on Ca(2+) signaling, platelets, endothelium
2.3.1 The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors
2.3.2 Platelets in Translational Research 2
2.3.3 The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis
2.3.4 Nitric Oxide Synthase Inhibitors (NOS-I)
2.3.5 Resistance to Receptor of Tyrosine Kinase
2.3.6 Oxidized Calcium Calmodulin Kinase and Atrial Fibrillation
2.3.7 Advanced Topics in Sepsis and the Cardiovascular System at its End Stage
2.4 Comorbidity of Diabetes and Aging
2.4.1 Heart and Aging Research in Genomic Epidemiology: 1700 MIs and 2300 coronary heart disease events among about 29 000 eligible patients
PART 3
Determinants of Cardiovascular Diseases
Genetics, Heredity and Genomics Discoveries
Introduction
3.1 Why cancer cells contain abnormal numbers of chromosomes (Aneuploidy)
3.1.1 Aneuploidy and Carcinogenesis
3.2 Functional Characterization of Cardiovascular Genomics: Disease Case Studies @ 2013 ASHG
3.3 Leading DIAGNOSES of Cardiovascular Diseases covered in Circulation: Cardiovascular Genetics, 3/2010 – 3/2013
3.3.1: Heredity of Cardiovascular Disorders
3.3.3: Hypertention and Atherosclerosis
3.3.5: Aging: Heart and Genetics
3.3.7: Hyperlipidemia, Hyper Cholesterolemia, Metabolic Syndrome
3.3.8: Stroke and Ischemic Stroke
3.3.9: Genetics and Vascular Pathologies and Platelet Aggregation, Cardiac Troponin T in Serum
3.3.10: Genomics and Valvular Disease
3.4 Commentary on Biomarkers for Genetics and Genomics of Cardiovascular Disease
PART 4
Individualized Medicine Guided by Genetics and Genomics Discoveries
4.1 Preventive Medicine: Cardiovascular Diseases
4.1.1 Personal Genomics for Preventive Cardiology Randomized Trial Design and Challenges
4.2 Gene-Therapy for Cardiovascular Diseases
4.2.1 Genetic Basis of Cardiomyopathy
4.3 Congenital Heart Disease/Defects
4.4 Pharmacogenomics for Cardiovascular Diseases
4.4.1 Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives
4.4.2 Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction
4.4.3 Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) Cohort
4.4.4 Genetic Variation in the β2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes
4.4.5 Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction – The GEOSTAT-1 Study
#3: Assembly of e-Books into e-Series
Example
Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC
- Volume One: Perspectives on Nitric Oxide in Disease Mechanisms
- Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
- Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics & Genomics
- Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
- Volume Five: Pharmaco-Therapies for Cardiovascular Diseases
- Volume Six: Interventional Cardiology and Cardiac Surgery
- Volume Seven: Cardiovascular Imaging for Disease Diagnosis and Guidance of Treatment
#4: Publishing of e-Series on Amazon.com
The BioMedicine e- Book Series has published of the following e-Books Titles with Amazon KINDLE:
http://www.amazon.com/dp/B00DINFFYC
Perspectives on Nitric Oxide in Disease Mechanisms (2013)
#5: Distribution of e-Series to Professional Associations via their Internet websites
In 2013 and Beyond, we are launching a Series of e-Books (electronic Books) in BioMedicine made up by articles published in this Open Access Online Scientific Journal.
Series Editor-in-Chief, Aviva Lev-Ari, PhD, RN has created over 800 articles in an inventory of 1,506 available on 12/30/2013 on http://pharmaceuticalintelligence.com. The Open Access Online Scientific Journal was launched on 4/2012.
BioMed e-Series was launched by Dr. Lev-Ari on 10/2013:
BioMed e-Series – Five Titles
- Series A: e-Books on Cardiovascular Diseases
- Series B: Frontiers in Genomics Research
- Series C: e-Books on Cancer & Oncology
- Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases
- Series E: Titles in the Strategic Plan for 2014-2015
Dr. Lev-Ari’s expertise in Cardiovascular Disease (CVD) is demonstrated in:
- Seven e-Books on CVD
Series A: e-Books on Cardiovascular Diseases
Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC
- Volume One: Perspectives on Nitric Oxide in Disease Mechanisms
- Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
- Volume Three: Etiologies of Cardiovascular Diseases – Epigenetics, Genetics & Genomics
- Volume Four: Therapeutic Promise: Cardiovascular Diseases, Regenerative & Translational Medicine
- Volume Five: Pharmaco-Therapies for Cardiovascular Diseases
- Volume Six: Interventional Cardiology and Cardiac Surgery
- Volume Seven: Cardiovascular Imaging for Disease Diagnosis and Guidance of Treatment
Scientific Journal Site Statistics
Date |
Views to Date |
# of articles |
NIH Clicks |
Nature Clicks |
6/24/2013 |
199,857 |
1,034 |
1,275 |
661 |
7/29/2013 | 217,356 | 1,138 | 1,389 | 705 |
12/1/2013 | 287,645 | 1,428 | 1,676 | 828 |
12/30/13 | 301,584 | 1,506 | 1,734 | 868 |
1/3/2014 | 303,342 | 1,541 | 1,736 | 868 |
Leave a Reply